AstraZeneca PLC

AstraZeneca PLC

AZN Stock Report Card

$

VolatilityTechnicalsSentimentProfitPerformanceEarningsAnalyst Price Targets

61%

Performance

Score:

100/100

AZN returned 2.92% in the last 12 months. Based on SPY's performance of -8.73%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

Score:

85/100

5 analysts offer 12-month price targets for AZN. Together, they have an average target of 80.5, the most optimistic target put AZN at 82 within 12-months and the most pessimistic has AZN at 79. These analyst ratings are from our partners at Financial Modeling Prep (https://site.financialmodelingprep.com/) and Alpha Vantage (https://www.alphavantage.co/).

Sentiment

Score:

70/100

AZN had a bullish sentiment score of 70.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.90 posts, 192.37 comments, and 574.29 likes per day.

Technicals

Score:

36/100

AZN receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

Score:

16/100

AZN has missed earnings 5 times in the last 20 quarters.

Profit

Score:

72/100

Out of the last 20 quarters, AZN has had 18 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

Score:

44/100

AZN has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

AstraZeneca PLC Summary

Nasdaq / AZN
Healthcare
Drug Manufacturers—General
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Pluto is a technology provider that provides you with information, software, and automation tools for the purpose of investment education, but it does not make investment recommendations of securities, investment strategies, or account types, either in general or individualized for you or any other subscriber. If you want to receive individualized investment advice, you should consult with your own financial adviser. Pluto also does not provide you with legal, tax, or accounting advice. You agree that you understand that Pluto is not an investment adviser or a broker-dealer and does not have a fiduciary duty to you or a duty to act in your best interests. Pluto can help you back-test the historical performance of strategies that you create, but it does not recommend strategies and reminds you that the historical performance of a strategy is not a reliable predictor of future results for that strategy. Pluto uses third-party information, for example, about securities market data, that it reasonably believes to be reliable, but it does not warrant that the information is complete, accurate, or up-to-date, and as discussed further below, Pluto does not provide any warranty of merchantability or warranty for a particular purpose for that third-party market data or other information. Investing involves risk, including the risk of loss, and you should not use the Pluto technology in connection with investments unless you are able to and intend to evaluate the technology and the risks and make your own self-directed investment decisions.

Power up your portfolio

Build a portfolio of your favorite stocks

Pluto makes it easy to build investing strategies and automate your portfolio
pluto logo
Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.